Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC DOI
Fabiana Perrone, Alessandro Leonetti, Marcello Tiseo

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(8), P. 1128 - 1132

Published: Aug. 1, 2024

Language: Английский

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial DOI Creative Commons
Bixia Tang, Yu Chen, Yu Jiang

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(10), P. e009662 - e009662

Published: Oct. 1, 2024

HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring manageable safety profile. This phase I trial investigated the safety, pharmacokinetics, immunogenicity preliminary efficacy of plus with anti-PD-1 antibody toripalimab in patients advanced solid tumors, especially focusing on melanoma.

Language: Английский

Citations

1
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer DOI Creative Commons
Martin Reck,

Tuli De,

Luis Paz‐Ares

et al.

Clinical Lung Cancer, Journal Year: 2024, Volume and Issue: 25(7), P. e362 - e368

Published: June 29, 2024

Language: Английский

Citations

0
Complete Favorable Response after Second-Line Immunotherapy in Stage IV Non-Small Lung Cancer with Visceral Metastases and Operated Brain Metastasis DOI Open Access
Roxana-Andreea Rahnea-Niţă, Laura Rebegea, Radu-Valeriu Toma

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 754 - 754

Published: July 16, 2024

Patients with non-small cell lung cancer (NSCLC) and brain metastatic disease have an unfavorable prognosis. The goal of the treatment in stage IV NSCLC is to increase survival rate improve quality life.

Language: Английский

Citations

0
A critical review: serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy DOI
Galip Can Uyar, Berna Öksüzoğlu, Osman Sütçüoğlu

et al.

Supportive Care in Cancer, Journal Year: 2024, Volume and Issue: 32(8)

Published: July 24, 2024

Language: Английский

Citations

0
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC DOI
Fabiana Perrone, Alessandro Leonetti, Marcello Tiseo

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(8), P. 1128 - 1132

Published: Aug. 1, 2024

Language: Английский

Citations

0